搜尋結果
1 天前 · Here we conducted a multicenter open-label, randomized phase 2 and 3 study to assess the safety and immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron ...
4 天前 · There was only a few reports on Omicron variant infections of severe or critical cases among children following this outbreak [5, 6]. Guangzhou Women and Children’s Medical Center, a national tertiary hospital for children in Guangdong Province, China, has been actively treating a large number of sick children, including referrals from other medical institutions.
1 天前 · Methods Study Participants VE of ≥2 original monovalent COVID-19 vaccine doses against COVID-19–related hospitalizations (December 19, 2021–October 29, 2023 ) across 34 Overcoming COVID-19 Network sites** was evaluated using a case-control design according to previously described methods (2,3).).
5 天前 · Analysis of risk factors associated with Omicron elderly patients with severe infections According to the univariate logistic regression analysis, it could be found that age > 80 years, having at least two comorbidities, and an O-N gene Ct value ≤ 20 on admission ...
2 天前 · have developed a broad-spectrum vaccine that can protect against severe acute respiratory syndrome ... (ancestral SARS-CoV-2 spike protein; four omicron variants BA.1, BA.5, BA.2. 75.2, XBB; SARS ...
2 天前 · EXPERT REACTION: COVID-19 vaccines likely prevented nearly 18,000 deaths in NSW's early Omicron era Australia's COVID-19 vaccination campaign likely prevented 17,760 deaths in NSW over-50s Over the course of the COVID-19 pandemic, the Australian Bureau of Statistics and the Australian Actuaries Institute have published regular reports on excess deaths caused by COVID-19.
4 天前 · In an ongoing, open-label, phase 2/3 study (ClinicalTrials.gov Identifier: NCT04927065), researchers assessed the safety and immunogenicity of 2 Omicron XBB-containing vaccine candidates. The vaccine candidates were monovalent mRNA-1273.815 (Omicron XBB.1.5) and bivalent mRNA-1273.231 (Omicron XBB.1.5 plus BA.4/BA.5), which were administered as third booster doses among a cohort of adults.
